|Study Description:||The goal of the extension part of this study is to learn if patients with GIST, |
who no longer respond to imatinib or nilotinib therapy that is given as part of
this study, would benefit from taking the other study drug they did not take.
In addition, the extension study now offers patients who received nilotinib in
the core study the possibility to be treated with imatinib prior to disease